FDA Delays Bimekizumab Decision, Again UCB, the maker of the IL-17 A/F inhibitor bimekizumab (BMK), has announced that the FDA decision on BMK use in adults with moderate to severe plaque psoriasis has been delayed until the 3rd quarter of 2023. https://t.co/u3wZp2xain https://t.co/pEldK1grb9